Focal segmental glomerulosclerosis: focus on cyclosporine


Citar

Texto integral

Resumo

Therapeutic strategies used in focal segmental glomerulosclerosis with special emphasis on cyclosporine are discussed

Sobre autores

L Kozlovskaya

Bibliografia

  1. Haas M., Spargo B.H., Coventry S. Increasing incidence of focal-segmental glomerulosclerosis among adult nephropathies: a 20-year renal biopsy study. Am. J. Kidney Dis. 1995; 26: 740-750
  2. Barisoni L., Valeri A., Radhakrishnan J. et al. Focal segmental glomerulosclerosis: a 20-year epidemiological perspective. J. Am. Soc. Nephrol. 1994; 5: 347 - 354
  3. Korbet S.M., Genchi R., Borok R.Z., Schwartz M.M. The racial difference of glomerular lesions in nephrotic adults. Am. J. Kidney Dis. 1996; 27: 647 - 651
  4. Lee D.Y., Kim W., Kang S.K. et al. Angiotensin-converting enzyme gene polymorphism in patients with minimal change nephrotic syndrome and focal segmental glomerulosclerosis. Nephron. 1997; 77(4): 471-473
  5. Gheissari A., Salehi M., Dastjerdi S.B. et al. Angiotensin-converting enzyme gene polymorphism and the progression rate of focal segmental glomerulosclerosis in Iranian children. Nephrology (Carlton). 2008; 13(8): 708-711
  6. Dixit M., Mansur A., Dixit N. et al. The role of ACE gene polymorphism in rapidity of progression of focal segmental glomerulosclerosis. J. Postgrad. Med. 2002; 48(4): 266-269
  7. Bantis C., Heering P.J., Luther Y. et al. Influence of cytokine gene polymorphisms on focal segmental glomerulosclerosis. Am. J. Nephrol. 2004; 24(4): 427-431
  8. Dai S., Wang Z., Pan X. et al. ACTN4 gene mutations and single nucleotide polymorphisms in idiopathic focal segmental glomerulosclerosis. Nephron. Clin. Pract. 2009; 111(2): c87-c94
  9. Munkert A., Helmchen U., Kemper MJ. et al. Characterization of the transcriptional regulation of the human MT1-MMP gene and association of risk reduction for focal-segmental glomerulosclerosis with two functional promoter SNPs. Nephrol. Dial. Transplant. 2009; 24(3): 735-742
  10. Barakat A.J., Arianas P., Glick A.D. et al. Focal sclerosing glomerulonephritis in a child with Laurence-Moon-Biedl syndrome. Child. Urol. Nephrol. 1990; 10: 109-111
  11. Hara M., Ichida F., Higuchi A. et al. Nephropathy associated with Charcot-Mari-Tooth disease. Int. J. Pediatr. Nephrol. 1984; 5: 99-102
  12. Scaglia F., Vogel H., Hawkins E.P. et al. Novel homoplasmic mutation in the mitochondrial tRNATyr gene associated with atypical mitochondrial cytopathy presenting with focal segmental glomerulosclerosis. Am. J. Med. Genet. 2003; 123A(2): 172-178
  13. Hotta O., Inoue C.N., Miyabayashi S. et al. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int. 2001; 59(4): 1236-1243
  14. Benetti E., Caridi G., Malaventura C. et al. A novel WT1 gene mutation in a three-generation family with progressive isolated focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2010; 5(4): 698-702
  15. Orloff M.S., Iyengar S.K., Winkler C.A. et al. Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population. Physiol. Genomics. 2005; 21(2): 212-221
  16. Schlöndorff J., Del Camino D., Carrasquillo R. et al. TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am. J. Physiol. Cell. Physiol. 2009; 296(3): C558-C569
  17. Kopp J.B., Smith M.W., Nelson G.W. et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat. Genet. 2008; 40(10): 1175-1184
  18. Freedman B.I., Hicks P.J., Bostrom M.A. et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 2009; 75(7): 736-745
  19. Freedman B.I., Hicks P.J., Bostrom M.A. et al. Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol. Dial. Transplant. 2009; 24(11): 3366-3371
  20. Löwik M.M., Groenen P.J., Levtchenko E.N. Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis - a review. Eur. J. Pediatr. 2009; 168(11): 1291-1304
  21. Franceschini N., North K.E., Kopp J.B. et al. NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: a HuGE review. Genet. Med. 2006; 8(2): 63-75
  22. Brown E.J., Schlöndorff J.S., Becker D.J. et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat. Genet. 2010; 42(1): 72-76
  23. Lavin P.J., Gbadegesin R., Damodaran T.V., Winn M.P. Therapeutic targets in focal and segmental glomerulosclerosis. Curr. Opin Nephrol. Hypertens. 2008; 17(4): 386 - 392
  24. Camici M. Urinary detection of podocyte injury. Biomed. Pharmacother. 2007; 61: 245-249
  25. D'Agati V.D. Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts). Kidney Int. 2008; 73(4): 399-406
  26. Yoshikawa N., Ito H., Akamatsu R. et al. Glomerular podocyte vacuolation in focal segmental glomerulosclerosis. Arch. Pathol. Lab. Med. 1986; 110(5): 394-398
  27. Chiang M.L., Hawkins E.P., Berry P.L. et al. Diagnostic and prognostic significance of glomerular epithelial cell vacuolization and podocyte effacementin children with minimal lesion nephrotic syndrome and focal segmental glomerulosclerosis: an ultrastructural study. Clin. Nephrol. 1988; 30(1): 8-14
  28. Kihara I., Tsuchida S., Yaoita E. et al. Podocyte detachment and epithelial cell reaction in focal segmental glomerulosclerosis with cellular variants. Kidney Int. Suppl. 1997; 63: S171-S176
  29. Schwartz M.M. The role of podocyte injury in the pathogenesis of focal segmental glomerulosclerosis. Ren. Fail. 2000; 22(6): 663-684
  30. Michaud J.L., Lemieux L.I., Dubé M. et al. Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant alpha actinin-4. J. Am. Soc. Nephrol. 2003; 14(5): 1200-1211
  31. Chen C.A., Hwang J.C., Guh J.Y. et al. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN treated rats. J. Lab. Clin. Med. 2006; 147(2): 74-82
  32. Shi S.F., Wang S.X., Zhang Y.K. et al. Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis. Ren. Fail. 2008; 30(5): 477-483
  33. Deegens J.K., Dijkman H.B., Borm GF. et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int. 2008; 74(12): 1568-1576
  34. Gassler N., Elger M., Kränzlin B. et al. Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat. Kidney Int. 2001; 60(1): 106-116
  35. Korbet S.M. Primary focal segmental focal segmental glomerulosclerosis. Brady H.R., Wilcox C.S. (ed.) Therapy in nephrology and hypertension. Saunders., 2003: 223-236
  36. Meyrier A., Collaborative Group of the Societe de Nephrologie. Cyclosporin in the treatment of neprosis. Am. J. Nephrol. 1989; 9(Suppl. 1): 65-71
  37. Melocoton T.L., Kamil E.S., Cohen A.H., Fine R.N. Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephritic syndrome. Am. J. Kidney Dis. 1991; 18: 583-588
  38. Cattran D.C. Cyclosporine in the treatment of idiopathic focal segmental glomerulosclerosis. Semin. Nephrol. 2003; 23(2): 234-241
  39. Chishti A.S., Sorof J.M., Brewer E.D., Kale A.S. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am. J. Kidney Dis. 2001; 38(4): 754-760
  40. Цыгин А.Н., Леонова А.В., Кучеренко А.Г. и др. Терапия циклоспорином А детей с фокально-сегментарным гломерулосклерозом. Вопросы современной педиатрии 2009; 5: 93 - 97
  41. Lieberman K.V., Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J. Am. Soc. Nephrol. 1996; 7(1): 56-63
  42. Сameron J.S. Focal segmental glomerulosclerosis in adults. Nephrol. Dial. Transplant. 2003; 18 (Suppl. 6): vi45-vi51
  43. Lee H.Y., Kim H.S., Kang C.M. et al. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea. Clin. Nephrol. 1995; 43(6): 375-381
  44. Cattran D.C., Appel G.B., Hebert L.A. et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999; 56(6): 2220-2226
  45. Heering P., Braun N., Müllejans R. et al.; German Collaborative Glomerulonephritis Study Group. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am. J. Kidney Dis. 2004; 43(1): 10-18
  46. Goumenos D.S., Tsagalis G., El Nahas A.M. et al.Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron. Clin. Pract. 2006; 104(2): c75-c82
  47. Braun N., Schmutzler F., Lange C. et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst. Rev. 2008; (3):CD003233
  48. Echigoya M.H., Obikane K., Nakashima T. et al. Glomerular localization of erythropoietin receptor mRNA and protein in neonatal and mature mouse kidney. Nephron. Exp. Nephrol. 2005; 100: e21-e29
  49. Logar C.M., Brinkkoetter P.T., Krofft R.D. et al. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int. 2007; 72: 489-498
  50. Joy M.S., Gipson D.S., Dike M. et al. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin. J. Am. Soc. Nephrol. 2009; 4(1): 39-47
  51. Joy M.S., Gipson D.S., Powell L. et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am. J. Kidney Dis. 2010; 55(1): 50-60
  52. Peyser A., Machardy N., Tarapore F. et al. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrol. 2010; 11: 2

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies